Zacks Investment Research on MSN
CAPR stock skyrockets 282% in a week: Here's what you need to know
Shares of Capricor Therapeutics CAPR have skyrocketed 281.9% this week. The massive stock price surge was observed after the ...
Capricor jumps after Phase 3 data show Deramiocel improves heart function and slows muscle decline in Duchenne muscular ...
Capricor shows positive HOPE-3 results with endpoints met, regulatory uncertainty, and a strong cash runway into 2026. Find ...
Capricor Therapeutics faces high regulatory risks for its DMD therapy. Get expert analysis on trial data and FDA challenges.
The Company plans to submit its response to the CRL, including the results from the HOPE-3 trial, to address the Agency's previous requests for additional data.
Piper Sandler raised the firm’s price target on Capricor Therapeutics (CAPR) to $45 from $20 and keeps an Overweight rating on the shares. The ...
In 105 boys and young men enrolled in the HOPE-3 trial, patients given deramiocel every three months for a year had 54% ...
Capricor Therapeutics shares gained after analysts said they believe the company can achieve profitability by 2028. The stock rose 8.4% to $29.14 and hit its 52-week high of $14.87 earlier in the ...
Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key ...
Investor Martin Shkreli's big biotech short position is blowing up after the stock's monumental rally over the past week.
Capricor Therapeutics (CAPR) announced that the European Medicines Agency, EMA, has granted both Orphan Drug and Advanced Therapy Medicinal Product, ATMP, designations to its lead asset, deramiocel, ...
US rare diseases focused biotech Capricor Therapeutics shares closed up 371% at $29.96, having leapt a staggering 500% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback